My Health Software, Blood Pressure News » Hypertension vaccine trial
logo logo

Hypertension vaccine study results have been released

Results from a small study testing the safety and tolerability of the hypertension vaccine have been released.

The vaccine

The group of researchers from the University Hospital of the Canton of Vaud, Switzerland tested the vaccine on 72 people with hypertension. They had an average age of 51.5 years.

According to Medical News Today report “The vaccine targets angiotensin II, a molecule that constricts blood vessels and raises blood pressure. Angiotensin II is already the indirect target of several blood pressure medications.”

Patients had injections at the start of the study and then at 4 and 12 weeks.

The results

Blood pressure changes were evaluated at week 14. Patients who had the vaccine reduced their systolic blood pressure by 5.6mmHg and diastolic blood pressure by 2.8mmHg.

The next step in developing the vaccine is for further trials. Researcher Dr Jones said the research is encouraging and “These investigators are pursuing novel approaches to hypertension control. While too early to evaluate whether this may be clinically useful, it is encouraging to see promising research results.


bottom KellieMyHS

About Kellie

Kellie is 37 years old and together with her brother Steve makes up the My Health Software team.

She helps on the websites and gathering news for the programs. Kellie worked in the medical industry prior to having her two children (8 and 6) and has a strong interest in self awareness and management of health conditions.


News "home delivered"

Note: These news headlines are now automatically displayed on the home page of the My Health Software applications for Windows.

The news is updated regularly, and you can click through to these items to read more.